Mackenzie Financial’s Relay Therapeutics RLAY Stock Holding History

Mackenzie Financial’s Portfolio RLAY Stock Details RLAY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-11,571	Closed	-$96K	–	1610
2024 Q1	$96K	Buy	+11,571	New	+$113K	﹤0.01%	1426

Other funds holding RLAY

SIAU

SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Mackenzie Financial's RLAY Position: Q2 2024 in Review

Mackenzie Financial sold out of Relay Therapeutics (RLAY) in Q2 2024, closing a stake of 11,571 shares — an estimated $96K sold.

Mackenzie Financial first reported a position in RLAY in Q1 2024 and held it in 1 quarter. The position peaked at $96K in Q1 2024. 178 funds tracked by Wall St. Rank hold RLAY as of Q2 2024.

Mackenzie Financial reported no remaining Relay Therapeutics position as of Q2 2024 after selling out during the quarter.
Mackenzie Financial sold 11,571 Relay Therapeutics shares in Q2 2024, an estimated $96K.
Mackenzie Financial first reported a position in Relay Therapeutics in Q1 2024 and held it in 1 quarter.
Mackenzie Financial's Relay Therapeutics position peaked at $96K in Q1 2024.
178 funds tracked by Wall St. Rank held Relay Therapeutics as of Q2 2024.

Based on Mackenzie Financial's 13F filing for Q2 2024, filed 14 Aug 2024.